STAT3 as a therapeutic target for glioblastoma

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 7, 2010, Pages 512-519

  Liu, Yan ^a   Li, Chenglong ^b   Lin, Jiayuh ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Cytokine; Glioblastoma; Glioblastoma stem cells; Growth factor; STAT3; STAT3 inhibitor

Indexed keywords

2,5 DIHYDROXYBENZENESULFONIC ACID; ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; CUCURBITACIN; JANUS KINASE 2 INHIBITOR; JSI 124; LEPTIN; LLL 3; MANUMYCIN; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; S 31 201; SORAFENIB; STA 21; STAT3 PROTEIN; TOCILIZUMAB; UNCLASSIFIED DRUG; WP 1066;

ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DEREGULATION; DRUG TARGETING; GLIOBLASTOMA; HUMAN; ONCOGENE; PROTEIN FUNCTION;

EID: 78649815101     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152010793498636     Document Type: Article

References (115)

1. Schwartzbaum, J.A.; Fisher, J.L.; Aldape, K.D.; Wrensch, M.Epidemiology and molecular pathology of glioma. Nat. Clin. Pract.Neurol., 2006, 2(9), 494-503.
2. Louis, D.N.; Ohgaki, H.; Wiestler, O.D.; Cavenee, W.K.; Burger, P.C.; Jouvet, A.; Scheithauer, B.W.; Kleihues, P. The 2007 WHOclassification of tumours of the central nervous system. ActaNeuropathol., 2007, 114(2), 97-109.
3. Wen, P.Y.; Kesari, S. Malignant gliomas in adults. N. Engl. J.Med., 2008, 359(5), 492-507.
4. Nicholas, M.K. Glioblastoma multiforme: evidence-based approachto therapy. Expert Rev. Anticancer Ther., 2007, 7(12 Suppl), S23-27.
5. Maher, E.A.; Furnari, F.B.; Bachoo, R.M.; Rowitch, D.H.; Louis, D.N.; Cavenee, W.K.; DePinho, R.A. Malignant glioma: geneticsand biology of a grave matter. Genes Dev., 2001, 15(11), 1311-1333.
6. de la Iglesia, N.; Puram, S.V.; Bonni, A. STAT3 regulation of glioblastoma pathogenesis. Curr. Mol. Med., 2009, 9(5), 580-590.
7. Brantley, E.C.; Benveniste, E.N. Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas.Mol. Cancer Res., 2008, 6(5), 675-684.
8. Levy, D.E.; Darnell, J.E., Jr. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell. Biol., 2002, 3(9), 651-662.
9. Battle, T.E.; Frank, D.A. The role of STATs in apoptosis. Curr.Mol. Med., 2002, 2(4), 381- 392.
10. Haura, E.B.; Turkson, J.; Jove, R. Mechanisms of disease: Insightsinto the emerging role of signal transducers and activators of transcription in cancer. Nat. Clin. Pract. Oncol., 2005, 2(6), 315-324.
11. Bromberg, J.F.; Wrzeszczynska, M.H.; Devgan, G.; Zhao, Y.; Pestell, R.G.; Albanese, C.; Darnell, J.E., Jr. Stat3 as an oncogene.Cell, 1999, 98(3), 295-303.
12. Bromberg, J.; Darnell, J.E., Jr. The role of STATs in transcriptionalcontrol and their impact on cellular function. Oncogene, 2000, 19(21), 2468-2473.
13. Bromberg, J. Stat proteins and oncogenesis. J. Clin. Invest., 2002, 109(9), 1139-1142.
14. Wegenka, U.M.; Buschmann, J.; Lutticken, C.; Heinrich, P.C.; Horn, F. Acute-phase response factor, a nuclear factor binding toacute-phase response elements, is rapidly activated by interleukin-6at the posttranslational level. Mol. Cell. Biol., 1993, 13(1), 276-288.
15. Ma, X.T.; Wang, S.; Ye, Y.J.; Du, R.Y.; Cui, Z.R.; Somsouk, M.Constitutive activation of Stat3 signaling pathway in humancolorectal carcinoma. World J. Gastroenterol., 2004, 10(11), 1569-1573.
16. Corvinus, F.M.; Orth, C.; Moriggl, R.; Tsareva, S.A.; Wagner, S.; Pfitzner, E.B.; Baus, D.; Kaufmann, R.; Huber, L.A.; Zatloukal, K.; Beug, H.; Ohlschlager, P.; Schutz, A.; Halbhuber, K.J.; Friedrich, K. Persistent STAT3 activation in colon cancer is associated withenhanced cell proliferation and tumor growth. Neoplasia, 2005, 7(6), 545-555.
17. Rahaman, S.O.; Vogelbaum, M.A.; Haque, S.J. Aberrant Stat3signaling by interleukin-4 in malignant glioma cells: involvementof IL-13Ralpha2. Cancer Res., 2005, 65(7), 2956-2963.
18. Yu, H.; Jove, R. The STATs of cancer--new molecular targetscome of age. Nat. Rev. Cancer, 2004, 4(2), 97-105.
19. Dasgupta, A.; Raychaudhuri, B.; Haqqi, T.; Prayson, R.; Van Meir, E.G.; Vogelbaum, M.; Haque, S.J. Stat3 activation is required forthe growth of U87 cell-derived tumours in mice. Eur. J. Cancer, 2009, 45(4), 677-684.
20. Carro, M.S.; Lim, W.K.; Alvarez, M.J.; Bollo, R.J.; Zhao, X.; Snyder, E.Y.; Sulman, E.P.; Anne, S.L.; Doetsch, F.; Colman, H.; Lasorella, A.; Aldape, K.; Califano, A.; Iavarone, A. Thetranscriptional network for mesenchymal transformation of braintumours. Nature, 2010, 463(7279), 318-325.
21. Sherry, M.M.; Reeves, A.; Wu, J.K.; Cochran, B.H. STAT3 isrequired for proliferation and maintenance of multipotency inglioblastoma stem cells. Stem Cells, 2009, 27(10), 2383-2392.
22. Kaptein, A.; Paillard, V.; Saunders, M. Dominant negative stat3mutant inhibits interleukin-6-induced Jak- STAT signaltransduction. J. Biol. Chem., 1996, 271(11), 5961-5964.
23. Wen, Z.; Zhong, Z.; Darnell, J.E., Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serinephosphorylation. Cell, 1995, 82(2), 241-250.
24. Jung, J.E.; Lee, H.G.; Cho, I.H.; Chung, D.H.; Yoon, S.H.; Yang, Y.M.; Lee, J.W.; Choi, S.; Park, J.W.; Ye, S.K.; Chung, M.H.STAT3 is a potential modulator of HIF-1-mediated VEGFexpression in human renal carcinoma cells. FASEB J., 2005, 19(10), 1296-1298.
25. Yu, H.; Pardoll, D.; Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer, 2009, 9(11), 798-809.
26. Heinrich, P.C.; Behrmann, I.; Muller-Newen, G.; Schaper, F.; Graeve, L. Interleukin-6-type cytokine signalling through thegp130/Jak/STAT pathway. Biochem. J., 1998, 334 (Pt 2), 297-314.
27. Hibi, M.; Murakami, M.; Saito, M.; Hirano, T.; Taga, T.; Kishimoto, T. Molecular cloning and expression of an IL-6 signaltransducer, gp130. Cell, 1990, 63(6), 1149-1157.
28. Murakami, M.; Hibi, M.; Nakagawa, N.; Nakagawa, T.; Yasukawa, K.; Yamanishi, K.; Taga, T.; Kishimoto, T. IL-6-inducedhomodimerization of gp130 and associated activation of a tyrosinekinase. Science, 1993, 260(5115), 1808-1810.
29. Stahl, N.; Farruggella, T.J.; Boulton, T.G.; Zhong, Z.; Darnell, J.E., Jr.; Yancopoulos, G.D. Choice of STATs and other substratesspecified by modular tyrosine-based motifs in cytokine receptors.Science, 1995, 267(5202), 1349-1353.
30. Gerhartz, C.; Heesel, B.; Sasse, J.; Hemmann, U.; Landgraf, C.; Schneider-Mergener, J.; Horn, F.; Heinrich, P.C.; Graeve, L. Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signaltransducer gp130. I. Definition of a novel phosphotyrosine motifmediating STAT1 activation. J. Biol. Chem., 1996, 271(22), 12991-12998.
31. Hemmann, U.; Gerhartz, C.; Heesel, B.; Sasse, J.; Kurapkat, G.; Grotzinger, J.; Wollmer, A.; Zhong, Z.; Darnell, J.E., Jr.; Graeve, L.; Heinrich, P.C.; Horn, F. Differential activation of acute phaseresponse factor/Stat3 and Stat1 via the cytoplasmic domain of theinterleukin 6 signal transducer gp130. II. Src homology SH2domains define the specificity of stat factor activation. J. Biol.Chem., 1996, 271(22), 12999-13007.
32. Heinrich, P.C.; Behrmann, I.; Haan, S.; Hermanns, H.M.; Muller-Newen, G.; Schaper, F. Principles of interleukin (IL)-6-typecytokine signalling and its regulation. Biochem. J., 2003, 374(Pt 1), 1-20.
33. Yoshimura, A. Regulation of cytokine signaling by the SOCS and Spred family proteins. Keio. J. Med., 2009, 58(2), 73-83.
34. Yoshimura, A.; Naka, T.; Kubo, M. SOCS proteins, cytokinesignalling and immune regulation. Nat. Rev. Immunol., 2007, 7(6), 454-465.
35. Yoshimura, A.; Mori, H.; Ohishi, M.; Aki, D.; Hanada, T. Negativeregulation of cytokine signaling influences inflammation. Curr.Opin. Immunol., 2003, 15(6), 704-708.
36. Groner, B.; Lucks, P.; Borghouts, C. The function of Stat3 in tumorcells and their microenvironment. Semin. Cell. Dev. Biol., 2008, 19(4), 341-350.
37. Zhang, X.; Guo, A.; Yu, J.; Possemato, A.; Chen, Y.; Zheng, W.; Polakiewicz, R.D.; Kinzler, K.W.; Vogelstein, B.; Velculescu, V.E.; Wang, Z.J. Identification of STAT3 as a substrate of receptorprotein tyrosine phosphatase T. Proc. Natl. Acad. Sci. USA, 2007, 104(10), 4060-4064.
38. Bienvenu, F.; Gascan, H.; Coqueret, O. Cyclin D1 repressesSTAT3 activation through a Cdk4-independent mechanism. J. Biol.Chem., 2001, 276(20), 16840-16847.
39. Ishii, Y.; Pirkmaier, A.; Alvarez, J.V.; Frank, D.A.; Keselman, I.; Logothetis, D.; Mandeli, J.; O'Connell, M.J.; Waxman, S.; Germain, D. Cyclin D1 overexpression and response to bortezomibtreatment in a breast cancer model. J. Natl. Cancer Inst., 2006, 98(17), 1238-1247.
40. Quintanilla-Martinez, L.; Kremer, M.; Specht, K.; Calzada-Wack, J.; Nathrath, M.; Schaich, R.; Hofler, H.; Fend, F. Analysis of signal transducer and activator of transcription 3 (Stat 3) pathwayin multiple myeloma: Stat 3 activation and cyclin D1 dysregulationare mutually exclusive events. Am. J. Pathol., 2003, 162(5), 1449-1461.
41. Meng, F.; Henson, R.; Wehbe-Janek, H.; Smith, H.; Ueno, Y.; Patel, T. The MicroRNA let-7a modulates interleukin-6-dependentSTAT-3 survival signaling in malignant human cholangiocytes. J.Biol. Chem., 2007, 282(11), 8256-8264.
42. Haura, E.B.; Zheng, Z.; Song, L.; Cantor, A.; Bepler, G. Activatedepidermal growth factor receptor-Stat-3 signaling promotes tumorsurvival in vivo in non-small cell lung cancer. Clin. Cancer Res., 2005, 11(23), 8288-8294.
43. Dauer, D.J.; Ferraro, B.; Song, L.; Yu, B.; Mora, L.; Buettner, R.; Enkemann, S.; Jove, R.; Haura, E.B. Stat3 regulates genes commonto both wound healing and cancer. Oncogene, 2005, 24(21), 3397-3408.
44. Inghirami, G.; Chiarle, R.; Simmons, W.J.; Piva, R.; Schlessinger, K.; Levy, D.E. New and old functions of STAT3: a pivotal targetfor individualized treatment of cancer. Cell Cycle, 2005, 4(9), 1131-1133.
45. Schlessinger, K.; Levy, D.E. Malignant transformation but notnormal cell growth depends on signal transducer and activator of transcription 3. Cancer Res., 2005, 65(13), 5828-5834.
46. Germain, D.; Frank, D.A. Targeting the cytoplasmic and nuclearfunctions of signal transducers and activators of transcription 3 forcancer therapy. Clin. Cancer Res., 2007, 13(19), 5665-5669.
47. Xu, Q.; Briggs, J.; Park, S.; Niu, G.; Kortylewski, M.; Zhang, S.; Gritsko, T.; Turkson, J.; Kay, H.; Semenza, G.L.; Cheng, J.Q.; Jove, R.; Yu, H. Targeting Stat3 blocks both HIF-1 and VEGFexpression induced by multiple oncogenic growth signalingpathways. Oncogene, 2005, 24(36), 5552-5560.
48. Niu, G.; Wright, K.L.; Ma, Y.; Wright, G.M.; Huang, M.; Irby, R.; Briggs, J.; Karras, J.; Cress, W.D.; Pardoll, D.; Jove, R.; Chen, J.; Yu, H. Role of Stat3 in regulating p53 expression and function.Mol. Cell. Biol., 2005, 25(17), 7432-7440.
49. Lin, J.; Tang, H.; Jin, X.; Jia, G.; Hsieh, J.T. p53 regulates Stat3phosphorylation and DNA binding activity in human prostatecancer cells expressing constitutively active Stat3. Oncogene, 2002, 21(19), 3082-3088.
50. Bonni, A.; Sun, Y.; Nadal-Vicens, M.; Bhatt, A.; Frank, D.A.; Rozovsky, I.; Stahl, N.; Yancopoulos, G.D.; Greenberg, M.E.Regulation of gliogenesis in the central nervous system by theJAK-STAT signaling pathway. Science, 1997, 278(5337), 477-483.
51. Rajan, P.; McKay, R.D. Multiple routes to astrocytic differentiationin the CNS. J. Neurosci., 1998, 18(10), 3620-3629.
52. Yoshimatsu, T.; Kawaguchi, D.; Oishi, K.; Takeda, K.; Akira, S.; Masuyama, N.; Gotoh, Y. Non-cell- autonomous action of STAT3in maintenance of neural precursor cells in the mouse neocortex.Development, 2006, 133(13), 2553-2563.
53. Rahaman, S.O.; Harbor, P.C.; Chernova, O.; Barnett, G.H.; Vogelbaum, M.A.; Haque, S.J. Inhibition of constitutively activeStat3 suppresses proliferation and induces apoptosis inglioblastoma multiforme cells. Oncogene, 2002, 21(55), 8404-8413.
54. Konnikova, L.; Kotecki, M.; Kruger, M.M.; Cochran, B.H.Knockdown of STAT3 expression by RNAi induces apoptosis inastrocytoma cells. BMC Cancer, 2003, 3, 23.
55. Birner, P.; Toumangelova-Uzeir, K.; Natchev, S.; Guentchev, M. STAT3 tyrosine phosphorylation influences survival inglioblastoma. J. Neurooncol., 2010, (in press). DOI:10.1007/S11060-010-0195-8.
56. Chautard, E.; Loubeau, G.; Tchirkov, A.; Chassagne, J.; Vermot-Desroches, C.; Morel, L.; Verrelle, P. Akt signaling pathway: atarget for radiosensitizing human malignant glioma. Neuro. Oncol., 2010, 12(5), 434- 443.
57. Reya, T.; Morrison, S.J.; Clarke, M.F.; Weissman, I.L. Stem cells, cancer, and cancer stem cells. Nature, 2001, 414(6859), 105-111.
58. Singh, S.K.; Clarke, I.D.; Terasaki, M.; Bonn, V.E.; Hawkins, C.; Squire, J.; Dirks, P.B. Identification of a cancer stem cell in humanbrain tumors. Cancer Res., 2003, 63(18), 5821-5828.
59. Singh, S.K.; Hawkins, C.; Clarke, I.D.; Squire, J.A.; Bayani, J.; Hide, T.; Henkelman, R.M.; Cusimano, M.D.; Dirks, P.B.Identification of human brain tumour initiating cells. Nature, 2004, 432(7015), 396-401.
60. Li, G.H.; Wei, H.; Lv, S.Q.; Ji, H.; Wang, D.L. Knockdown of STAT3 expression by RNAi suppresses growth and inducesapoptosis and differentiation in glioblastoma stem cells. Int. J.Oncol., 2010, 37(1), 103-110.
61. Xu, Y.; Stamenkovic, I.; Yu, Q. CD44 attenuates activation of thehippo signaling pathway and is a prime therapeutic target forglioblastoma. Cancer Res., 2010, 70(6), 2455-2464.
62. Villalva, C.; Martin-Lanneree, S.; Cortes, U.; Dkhissi, F.; Wager, M.; Le Corf, A.; Tourani, J.; Dusanter-Fourt, I.; Turhan, A.; Karayan-Tapon, L. STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: A potential for targeted therapy? Int. J. Cancer, 2010. DOI:10.1002/ijc.25416.
63. Lee, J.L.; Wang, M.J.; Chen, J.Y. Acetylation and activation of STAT3 mediated by nuclear translocation of CD44. J. Cell. Biol., 2009, 185(6), 949-957.
64. Wei, J.; Barr, J.; Kong, L.Y.; Wang, Y.; Wu, A.; Sharma, A.K.; Gumin, J.; Henry, V.; Colman, H.; Priebe, W.; Sawaya, R.; Lang, F.F.; Heimberger, A.B. Glioblastoma cancer-initiating cells inhibitT-cell proliferation and effector responses by the signal transducersand activators of transcription 3 pathway. Mol. Cancer Ther., 2010, 9(1), 67-78.
65. Fan, X.; Khaki, L.; Zhu, T.S.; Soules, M.E.; Talsma, C.E.; Gul, N.; Koh, C.; Zhang, J.; Li, Y.M.; Maciaczyk, J.; Nikkhah, G.; Dimeco, F.; Piccirillo, S.; Vescovi, A.L.; Eberhart, C.G. NOTCH pathwayblockade depletes CD133-positive glioblastoma cells and inhibitsgrowth of tumor neurospheres and xenografts. Stem Cells, 2009, 28(1), 5-16.
66. Yuki, K.; Natsume, A.; Yokoyama, H.; Kondo, Y.; Ohno, M.; Kato, T.; Chansakul, P.; Ito, M.; Kim, S.U.; Wakabayashi, T.Induction of oligodendrogenesis in glioblastoma-initiating cells byIFN-mediated activation of STAT3 signaling. Cancer Lett., 2009, 284(1), 71-79.
67. Wang, H.; Lathia, J.D.; Wu, Q.; Wang, J.; Li, Z.; Heddleston, J.M.; Eyler, C.E.; Elderbroom, J.; Gallagher, J.; Schuschu, J.; MacSwords, J.; Cao, Y.; McLendon, R.E.; Wang, X.F.; Hjelmeland, A.B.; Rich, J.N. Targeting interleukin 6 signalingsuppresses glioma stem cell survival and tumor growth. Stem Cells, 2009, 27(10), 2393-2404.
68. Wei, J.; Barr, J.; Kong, L.Y.; Wang, Y.; Wu, A.; Sharma, A.K.; Gumin, J.; Henry, V.; Colman, H.; Priebe, W.; Sawaya, R.; Lang, F.F.; Heimberger, A.B. Glioblastoma cancer-initiating cells inhibitT-cell proliferation and effector responses by the signal transducersand activators of transcription 3 pathway. Mol. Cancer Ther., 2008, 9(1), 67-78.
69. Holland, S.M.; DeLeo, F.R.; Elloumi, H.Z.; Hsu, A.P.; Uzel, G.; Brodsky, N.; Freeman, A.F.; Demidowich, A.; Davis, J.; Turner, M.L.; Anderson, V.L.; Darnell, D.N.; Welch, P.A.; Kuhns, D.B.; Frucht, D.M.; Malech, H.L.; Gallin, J.I.; Kobayashi, S.D.; Whitney, A.R.; Voyich, J.M.; Musser, J.M.; Woellner, C.; Schaffer, A.A.; Puck, J.M.; Grimbacher, B. STAT3 mutations in the hyper-IgEsyndrome. N. Engl. J. Med., 2007, 357(16), 1608-1619.
70. Levy, D.E.; Loomis, C.A. STAT3 signaling and the hyper-IgEsyndrome. N. Engl. J. Med., 2007, 357(16), 1655-1658.
71. Minegishi, Y.; Saito, M.; Tsuchiya, S.; Tsuge, I.; Takada, H.; Hara, T.; Kawamura, N.; Ariga, T.; Pasic, S.; Stojkovic, O.; Metin, A.; Karasuyama, H. Dominant-negative mutations in the DNA-bindingdomain of STAT3 cause hyper-IgE syndrome. Nature, 2007, 448(7157), 1058-1062.
72. Papanastasiou, A.D.; Mantagos, S.; Papanastasiou, D.A.; Zarkadis, I.K. A novel mutation in the signal transducer and activator of transcription 3 (STAT3) gene, in hyper-IgE syndrome. Mol.Immunol., 2010, 47(7-8), 1629-1634.
73. Picard, C. STAT3 mutation identified in patients with Hyper-IgEsyndrome. Med. Sci. (Paris), 2008, 24(3), 242-243.
74. Tangye, S.G.; Cook, M.C.; Fulcher, D.A. Insights into the role of STAT3 in human lymphocyte differentiation as revealed by thehyper-IgE syndrome. J. Immunol., 2009, 182(1), 21-28.
75. Wjst, M.; Lichtner, P.; Meitinger, T.; Grimbacher, B. STAT3single-nucleotide polymorphisms and STAT3 mutations associatedwith hyper-IgE syndrome are not responsible for increased serumIgE serum levels in asthma families. Eur. J. Hum. Genet., 2009, 17(3), 352-356.
76. Woellner, C.; Gertz, E.M.; Schaffer, A.A.; Lagos, M.; Perro, M.; Glocker, E.O.; Pietrogrande, M.C.; Cossu, F.; Franco, J.L.; Matamoros, N.; Pietrucha, B.; Heropolitanska-Pliszka, E.; Yeganeh, M.; Moin, M.; Espanol, T.; Ehl, S.; Gennery, A.R.; Abinun, M.; Breborowicz, A.; Niehues, T.; Kilic, S.S.; Junker, A.; Turvey, S.E.; Plebani, A.; Sanchez, B.; Garty, B.Z.; Pignata, C.; Cancrini, C.; Litzman, J.; Sanal, O.; Baumann, U.; Bacchetta, R.; Hsu, A.P.; Davis, J.N.; Hammarstrom, L.; Davies, E.G.; Eren, E.; Arkwright, P.D.; Moilanen, J.S.; Viemann, D.; Khan, S.; Marodi, L.; Cant, A.J.; Freeman, A.F.; Puck, J.M.; Holland, S.M.; Grimbacher, B. Mutations in STAT3 and diagnostic guidelines forhyper-IgE syndrome. J. Allergy Clin. Immunol., 2010, 125(2), 424-432 (in press), e428.
77. Xie, L.; Hu, X.; Li, Y.; Zhang, W.; Chen, L. Hyper-IgE syndromewith STAT3 mutation: a case report in Mainland China. Clin. Dev.Immunol., 2010, 2010, 289873.
78. Van Wagoner, N.J.; Benveniste, E.N. Interleukin-6 expression and regulation in astrocytes. J. Neuroimmunol., 1999, 100(1-2), 124-139.
79. Liu, Q.; Li, G.; Li, R.; Shen, J.; He, Q.; Deng, L.; Zhang, C.; Zhang, J. IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines. J. Neurooncol., 2010,(in press) DOI: 10.1007/s11060-010- 0158-0.
80. Li, R.; Li, G.; Deng, L.; Liu, Q.; Dai, J.; Shen, J.; Zhang, J. IL-6augments the invasiveness of U87MG human glioblastomamultiforme cells via up-regulation of MMP-2 and fascin-1. Oncol.Rep., 2010, 23(6), 1553-1559.
81. Loeffler, S.; Fayard, B.; Weis, J.; Weissenberger, J. Interleukin-6induces transcriptional activation of vascular endothelial growthfactor (VEGF) in astrocytes in vivo and regulates VEGF promoteractivity in glioblastoma cells via direct interaction between STAT3and Sp1. Int. J. Cancer, 2005, 115(2), 202-213.
82. Weissenberger, J.; Loeffler, S.; Kappeler, A.; Kopf, M.; Lukes, A.; Afanasieva, T.A.; Aguzzi, A.; Weis, J. IL-6 is required for gliomadevelopment in a mouse model. Oncogene, 2004, 23(19), 3308-3316.
83. Wong, A.J.; Bigner, S.H.; Bigner, D.D.; Kinzler, K.W.; Hamilton, S.R.; Vogelstein, B. Increased expression of the epidermal growthfactor receptor gene in malignant gliomas is invariably associatedwith gene amplification. Proc. Natl. Acad. Sci. USA, 1987, 84(19), 6899-6903.
84. Lo, H.W.; Cao, X.; Zhu, H.; Ali-Osman, F. Constitutively activatedSTAT3 frequently coexpresses with epidermal growth factorreceptor in high-grade gliomas and targeting STAT3 sensitizesthem to Iressa and alkylators. Clin. Cancer Res., 2008, 14(19), 6042-6054.
85. Ghosh, M.K.; Sharma, P.; Harbor, P.C.; Rahaman, S.O.; Haque, S.J. PI3K-AKT pathway negatively controls EGFR-dependentDNA-binding activity of Stat3 in glioblastoma multiforme cells.Oncogene, 2005, 24(49), 7290-7300.
86. Riolfi, M.; Ferla, R.; Del Valle, L.; Pina-Oviedo, S.; Scolaro, L.; Micciolo, R.; Guidi, M.; Terrasi, M.; Cetto, G.L.; Surmacz, E.Leptin and its receptor are overexpressed in brain tumors and correlate with the degree of malignancy. Brain Pathol., 2010, 20(2), 481-489.
87. Ren, Y.; Zhou, X.; Mei, M.; Yuan, X.B.; Han, L.; Wang, G.X.; Jia, Z.F.; Xu, P.; Pu, P.Y.; Kang, C.S. MicroRNA-21 inhibitorsensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN- wild type) to taxol. BMC Cancer, 2010, 10, 27.
88. Strakova, N.; Ehrmann, J.; Dzubak, P.; Bouchal, J.; Kolar, Z. Thesynthetic ligand of peroxisome proliferator-activated receptorgammaciglitazone affects human glioblastoma cell lines. J.Pharmacol. Exp. Ther., 2004, 309(3), 1239-1247.
89. Strakova, N.; Ehrmann, J.; Bartos, J.; Malikova, J.; Dolezel, J.; Kolar, Z. Peroxisome proliferator-activated receptors (PPAR)agonists affect cell viability, apoptosis and expression of cell cyclerelated proteins in cell lines of glial brain tumors. Neoplasma, 2005, 52(2), 126-136.
90. Cellai, I.; Benvenuti, S.; Luciani, P.; Galli, A.; Ceni, E.; Simi, L.; Baglioni, S.; Muratori, M.; Ottanelli, B.; Serio, M.; Thiele, C.J.; Peri, A. Antineoplastic effects of rosiglitazone and PPARgammatransactivation in neuroblastoma cells. Br. J. Cancer, 2006, 95(7), 879-888.
91. Grommes, C.; Landreth, G.E.; Sastre, M.; Beck, M.; Feinstein, D.L.; Jacobs, A.H.; Schlegel, U.; Heneka, M.T. Inhibition of invivo glioma growth and invasion by peroxisome proliferatoractivatedreceptor gamma agonist treatment. Mol. Pharmacol., 2006, 70(5), 1524-1533.
92. Chearwae, W.; Bright, J.J. PPARgamma agonists inhibit growthand expansion of CD133+ brain tumour stem cells. Br. J. Cancer, 2008, 99(12), 2044-2053.
93. Ehrmann, J.; Strakova, N.; Vrzalikova, K.; Hezova, R.; Kolar, Z. Expression of STATs and their inhibitors SOCS and PIAS in braintumors. In vitro and in vivo study. Neoplasma, 2008, 55(6), 482-487.
94. Brantley, E.C.; Nabors, L.B.; Gillespie, G.Y.; Choi, Y.H.; Palmer, C.A.; Harrison, K.; Roarty, K.; Benveniste, E.N. Loss of proteininhibitors of activated STAT-3 expression in glioblastomamultiforme tumors: implications for STAT-3 activation and geneexpression. Clin. Cancer Res., 2008, 14(15), 4694- 4704.
95. Veeriah, S.; Brennan, C.; Meng, S.; Singh, B.; Fagin, J.A.; Solit, D.B.; Paty, P.B.; Rohle, D.; Vivanco, I.; Chmielecki, J.; Pao, W.; Ladanyi, M.; Gerald, W.L.; Liau, L.; Cloughesy, T.C.; Mischel, P.S.; Sander, C.; Taylor, B.; Schultz, N.; Major, J.; Heguy, A.; Fang, F.; Mellinghoff, I.K.; Chan, T.A. The tyrosine phosphatasePTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc. Natl.Acad. Sci. USA, 2009, 106(23), 9435-9440.
96. Ohgaki, H.; Kleihues, P. Epidemiology and etiology of gliomas.Acta Neuropathol, 2005, 109(1), 93-108.
97. Qin, H.; Roberts, K.L.; Niyongere, S.A.; Cong, Y.; Elson, C.O.; Benveniste, E.N. Molecular mechanism of lipopolysaccharideinducedSOCS-3 gene expression in macrophages and microglia. J.Immunol., 2007, 179(9), 5966-5976.
98. Starr, R.; Willson, T.A.; Viney, E.M.; Murray, L.J.; Rayner, J.R.; Jenkins, B.J.; Gonda, T.J.; Alexander, W.S.; Metcalf, D.; Nicola, N.A.; Hilton, D.J. A family of cytokine-inducible inhibitors of signalling. Nature, 1997, 387(6636), 917-921.
99. He, B.; You, L.; Uematsu, K.; Zang, K.; Xu, Z.; Lee, A.Y.; Costello, J.F.; McCormick, F.; Jablons, D.M. SOCS-3 is frequentlysilenced by hypermethylation and suppresses cell growth in humanlung cancer. Proc. Natl. Acad. Sci. USA, 2003, 100(24), 14133-14138.
100. Weber, A.; Hengge, U.R.; Bardenheuer, W.; Tischoff, I.; Sommerer, F.; Markwarth, A.; Dietz, A.; Wittekind, C.; Tannapfel, A. SOCS-3 is frequently methylated in head and neck squamouscell carcinoma and its precursor lesions and causes growthinhibition. Oncogene, 2005, 24(44), 6699-6708.
101. Sutherland, K.D.; Lindeman, G.J.; Choong, D.Y.; Wittlin, S.; Brentzell, L.; Phillips, W.; Campbell, I.G.; Visvader, J.E.Differential hypermethylation of SOCS genes in ovarian and breastcarcinomas. Oncogene, 2004, 23(46), 7726-7733.
102. Zhou, H.; Miki, R.; Eeva, M.; Fike, F.M.; Seligson, D.; Yang, L.; Yoshimura, A.; Teitell, M.A.; Jamieson, C.A.; Cacalano, N.A.Reciprocal regulation of SOCS 1 and SOCS3 enhances resistanceto ionizing radiation in glioblastoma multiforme. Clin. Cancer Res., 2007, 13(8), 2344-2353.
103. de la Iglesia, N.; Konopka, G.; Lim, K.L.; Nutt, C.L.; Bromberg, J.F.; Frank, D.A.; Mischel, P.S.; Louis, D.N.; Bonni, A. Deregulation of a STAT3-interleukin 8 signaling pathwaypromotes human glioblastoma cell proliferation and invasiveness.J. Neurosci., 2008, 28(23), 5870-5878.
104. Li, G.H.; Wei, H.; Chen, Z.T.; Lv, S.Q.; Yin, C.L.; Wang, D.L.STAT3 silencing with lentivirus inhibits growth and inducesapoptosis and differentiation of U251 cells. J. Neurooncol., 2009, 91(2), 165-174.
105. Senft, C.; Priester, M.; Polacin, M.; Schroder, K.; Seifert, V.; Kogel, D.; Weissenberger, J. Inhibition of the JAK-2/STAT3signaling pathway impedes the migratory and invasive potential of human glioblastoma cells. J. Neurooncol., 2010, (in press) DOI:10.1007/s11060-010-0273-y
106. Kim, S.R.; Bae, M.K.; Kim, J.Y.; Wee, H.J.; Yoo, M.A.; Bae, S.K.Aspirin induces apoptosis through the blockade of IL-6-STAT3signaling pathway in human glioblastoma A172 cells. Biochem.Biophys. Res. Commun., 2009, 387(2), 342-347.
107. Cuevas, P.; Diaz-Gonzalez, D.; Sanchez, I.; Lozano, R.M.; Gimenez-Gallego, G.; Dujovny, M. Dobesilate inhibits theactivation of signal transducer and activator of transcription 3, and the expression of cyclin D1 and bcl-XL in glioma cells. Neurol.Res., 2006, 28(2), 127-130.
108. Su, Y.; Li, G.; Zhang, X.; Gu, J.; Zhang, C.; Tian, Z.; Zhang, J. JSI-124 inhibits glioblastoma multiforme cell proliferation throughG(2)/M cell cycle arrest and apoptosis augment. Cancer Biol.Ther., 2008, 7(8), 1243-1249.
109. Fuh, B.; Sobo, M.; Cen, L.; Josiah, D.; Hutzen, B.; Cisek, K.; Bhasin, D.; Regan, N.; Lin, L.; Chan, C.; Caldas, H.; DeAngelis, S.; Li, C.; Li, P.K.; Lin, J. LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in amouse glioblastoma model. Br. J. Cancer, 2009, 100(1), 106-112.
110. Dixit, D.; Sharma, V.; Ghosh, S.; Koul, N.; Mishra, P.K.; Sen, E.Manumycin inhibits STAT3, telomerase activity, and growth of glioma cells by elevating intracellular reactive oxygen speciesgeneration. Free Radic. Biol. Med., 2009, 47(4), 364-374.
111. Siegelin, M.D.; Raskett, C.M.; Gilbert, C.A.; Ross, A.H.; Altieri, D.C. Sorafenibexerts anti-glioma activity in vitro and in vivo.Neurosci. Lett., 2010, 165-170.
112. Yang, F.; Brown, C.; Buettner, R.; Hedvat, M.; Starr, R.; Scuto, A.; Schroeder, A.; Jensen, M.; Jove, R. Sorafenib induces growth arrestand apoptosis of human glioblastoma cells through thedephosphorylation of signal transducers and activators of transcription 3. Mol. Cancer Ther., 2010, 9(4), 953-962.
113. Kudo, M.; Jono, H.; Shinriki, S.; Yano, S.; Nakamura, H.; Makino, K.; Hide, T.; Muta, D.; Ueda, M.; Ota, K.; Ando, Y.; Kuratsu, J. Antitumor effect of humanized anti-interleukin-6 receptor antibody(tocilizumab) on glioma cell proliferation. Laboratoryinvestigation. J. Neurosurg., 2009, 111(2), 219-225.
114. Hussain, S.F.; Kong, L.Y.; Jordan, J.; Conrad, C.; Madden, T.; Fokt, I.; Priebe, W.; Heimberger, A.B. A novel small moleculeinhibitor of signal transducers and activators of transcription 3reverses immune tolerance in malignant glioma patients. CancerRes., 2007, 67(20), 9630-9636.
115. Ferrajoli, A.; Faderl, S.; Van, Q.; Koch, P.; Harris, D.; Liu, Z.; Hazan-Halevy, I.; Wang, Y.; Kantarjian, H.M.; Priebe, W.; Estrov, Z. WP1066 disrupts Janus kinase-2 and induces caspase-dependentapoptosis in acute myelogenous leukemia cells. Cancer Res., 2007, 67(23), 11291-11299.